The European Medicines Agency is reviewing data on monoclonal antibody use for COVID-19
The EMA is reviewing available data on the use of casirivimab, imdevimab, bamlanivimab and etesevimab, with the intention of providing a harmonised scientific opinion at EU level to support national decision making on their possible use before a formal authorisation is issued.
Source:
European Medicines Agency
SPS commentary:
Preliminary results of studies looking into the effects of the combinations casirivimab/imdevimab and bamlanivimab/etesevimab in outpatients with COVID-19 who do not need supplemental oxygen indicate they reduced the viral load more than placebo and led to fewer COVID-19-related medical visits and hospitalisations.
The EMA announced the start of a rolling review of the antibody combination casirivimab and imdevimab earlier this week.